Search Results
Nov 10, 2025, 09:00 ET Wellcare to Offer Medicare Advantage and Medicare Prescription Drug Plans in 205 Texas Counties in 2026
must have one or more of the following chronic conditions: cancer, cardiovascular disorders, chronic and disabling mental health conditions, chronic lung disorders, diabetes. There are other eligible conditions not listed. Eligibility for this benefit cannot be guaranteed based solely on your condition.
More news about: Superior HealthPlan
Nov 10, 2025, 08:30 ET IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications.
More news about: IceCure Medical
Nov 10, 2025, 08:00 ET Brainomix Recognized in Global Health Tech Competition for Its Innovative Brainomix 360 Stroke Technology
Nov. 10, 2025 /PRNewswire/ -- Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has been named a winner in the American Heart Association's Health Tech Competition at Scientific Sessions 2025 in New Orleans. The company
More news about: Brainomix
Nov 10, 2025, 07:00 ET CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
include, but are not limited to CalciMedica's belief that treatment with Auxora reduces IL-17-related inflammation in kidney and lung, reduces IL-6-producing CD4 cells in the lung, and significantly improves kidney function which reinforces the mechanistic rationale for Auxora as a potential treatment for
More news about: CalciMedica, Inc.
Nov 10, 2025, 07:00 ET Freenome Appoints Industry Veteran Rob Guigley as Chief Commercial Officer to Drive Commercial Strategy, As Agreement with Exact Sciences Clears Antitrust Review
infrastructure following recent CLIA lab certification and early access program for key health system partners, with new test launches for colorectal cancer, lung cancer and other indications planned in 2026 – – In previously announced
More news about: Freenome Holdings, Inc.
Nov 09, 2025, 20:55 ET Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
global Phase 3 studies of sac-TMT 4 mg/kg Q2W in advanced EC, which were sponsored and led by MSD. OptiTROP-Lung03 On November 8, Professor Fang Wenfeng from the Cancer Center of Sun Yat-sen University delivered an oral
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 09, 2025, 06:30 ET Kyphosis Solution: Forme® Recognized for Smart Corrective Clothing by Expert Consumers
begin as flexible misalignments, chronic slouching can cause the curvature to become more fixed over time. This leads to pain, stiffness, and reduced lung capacity. Health experts warn that kyphosis and related conditions are no longer confined to older adults. They are now affecting
More news about: ExpertConsumers.org
Nov 08, 2025, 06:30 ET Tech Neck Solution: Forme®'s Smart Clothing Proven to Relieve Neck and Shoulder Strain - Report by Expert Consumers
story began with a personal mission. The company's founder, an orthopedic surgeon, developed the first prototype to help his mother, who suffered from lung compression and poor posture while battling cancer. That early innovation has since evolved into a clinically informed posturewear line trusted by users
More news about: ExpertConsumers.org
Nov 07, 2025, 17:14 ET Boehringer awarded FDA Commissioner's National Priority Voucher for HERNEXEOS® in HER2 lung cancer
About non-small cell lung cancer (NSCLC) Lung cancer claims more lives than any other cancer type1 and the incidence is set to increase to over 3 million cases worldwide by 2040.5 NSCLC is the most common type of lung cancer.1 The condition
More news about: Boehringer Ingelheim
Nov 07, 2025, 11:30 ET Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74
the HARMONi-A study, a Phase III study evaluating ivonescimab combined with chemotherapy for the treatment of EGFR-mutated non-squamous non-small cell lung cancer (nsq-NSCLC) following EGFR-TKI progression, were selected as a "Late-Breaking Abstract" (LBA) for the 40th Annual Meeting of the Society for
More news about: Akeso, Inc.
Nov 07, 2025, 09:05 ET Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025
presented a comparative analysis demonstrating that AI can standardize tumor immune phenotyping across multiple cancer types, including non-small cell lung, colorectal, and urothelial cancers. When assessing tumor and stromal segmentation, Lunit SCOPE IO showed high concordance with pathologist assessments
More news about: Lunit
Nov 07, 2025, 09:00 ET Marengo Late-Breaking Oral Presentation Highlights Single-Agent, Pan Tumor Activity of Invikafusp Alfa Across PD-1-Resistant Cancers in Phase 2 Clinical Trial at SITC 2025
seven major tumor types — colorectal, gastric, lung, breast, GEJ, head and neck, and bladder cancersResponses by indication include gastrointestinal (GI) tumors (28% ORR, 78% DCR), colorectal cancer (CRC) (33% ORR, 67% DCR), and non-small cell lung cancer (NSCLC) (20% ORR, 80% DCR)Target
More news about: Marengo Therapeutics
Nov 07, 2025, 08:00 ET Coreline Soft Unveils AVIEW 2.0 at RSNA 2025: Next-Generation AI Platform Redefining Radiology Workflow Standards
AVIEW 2.0 represents a paradigm shift from task-specific tools to an integrated diagnostic ecosystem. The platform seamlessly combines lung-cancer screening (LCS), coronary-artery calcium scoring (CAC), and COPD quantification into a single, continuous analytical pipeline. Clinical validation
More news about: Coreline Soft
Nov 07, 2025, 08:00 ET PRM Pharma Announces Nationwide Availability of HemiClor® (Chlorthalidone) 12.5 mg: The First FDA-Approved Low-Dose Chlorthalidone Tablet Aligned With Hypertension Guidelines
have made it a cornerstone of hypertension management for more than 50 years. Landmark trials such as ALLHAT and SHEP (sponsored by the National Heart, Lung and Blood Institute) demonstrated that treatment regimens based on stepped-care therapy starting with once-daily 12.5 mg chlorthalidone significantly
More news about: PRM Pharma, LLC
Nov 07, 2025, 08:00 ET Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025
to expand the potential of its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes's lab at the University of Edinburgh, is based in Edinburgh and London. Learn more by visiting
More news about: Resolution Therapeutics
Nov 07, 2025, 07:00 ET Gundry MD Launches the Total Body Transformation Course: A Breakthrough Weight Loss Program to Help People Look and Feel Years Younger
Gundry MD, Dr. Steven Gundry was one of the world's top cardiothoracic surgeons. Currently, he's the medical director at The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Santa Barbara, California where he's spent the past 25 years helping people restore
More news about: Gundry MD
Nov 07, 2025, 03:34 ET aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
that, "aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing it in patients with a type of lung disease known as pulmonary sarcoidosis, which impacts the lungs and lymph nodes." Based on this news, shares of aTyr traded down by more than 81% in
More news about: DJS Law Group LLP
Nov 06, 2025, 20:00 ET Fosun International Honored with Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025
monoclonal antibody independently developed by Fosun, is the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC). To date, it has been approved for marketing in nearly 40 countries and regions, including China, the European Union, the United Kingdom,
More news about: Fosun
Nov 06, 2025, 16:05 ET Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast
More news about: Trevi Therapeutics, Inc.
Nov 06, 2025, 11:00 ET California Seniors Now Have More Medicare Advantage and Medicare Prescription Drug Plans to Choose from in 2026 Thanks to Health Net and Centene
must have one or more of the following chronic conditions: cancer, cardiovascular disorders, chronic and disabling mental health conditions, chronic lung disorders, diabetes. There are other eligible conditions not listed. Eligibility for this benefit cannot be guaranteed based solely on your condition.
More news about: Health Net
Nov 06, 2025, 10:58 ET Top U.S. Stem-Cell Provider Named as Celebrity Demand Soars
patients across multiple conditions, including orthopedic injuries, autoimmune disorders, and chronic diseases. Examples include a COPD patient whose lung function improved from 28 to nearly 50 percent, and a kidney-disease patient who avoided dialysis for more than 20 years after ISCC treatment.
More news about: iMedstem LLC DBA Innovations Stem Cell Center
Nov 06, 2025, 10:39 ET River Oaks Imaging & Diagnostic Center Celebrates Grand Opening with Ribbon Cutting and Community Support
very high standard of care including ultra-low-dose exams, premium image quality, and advanced diagnostic analysis for common CT scans such as low dose lung screening and cardiac calcium scoring. uDR® 780i is a powerful ceiling-mounted X-ray system designed
More news about: United Imaging Healthcare Co., Ltd.
Nov 06, 2025, 09:00 ET GC Biopharma Supports New Insights into Education, Safety, and Patient Outcomes in Ig Therapy Care at the 2025 IgNS Annual Meeting
particularly patients with risk factors. Transfusion-Related Acute Lung Injury: Noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) may occur. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal
More news about: GC Biopharma USA Inc.
Nov 06, 2025, 08:00 ET OncoHost Wins 'Proteomics Innovation of the Year' at the BioTech Breakthrough Awards
offering - PROphetNSCLC®, is the first liquid biopsy proteomics test designed to guide immunotherapy treatment choices in late-stage non-small cell lung cancer (NSCLC). Available throughout the U.S., PROphetNSCLC® provides clinicians with actionable insights based on a single pre-treatment blood sample
More news about: OncoHost
Nov 06, 2025, 08:00 ET Wellcare of Georgia Enhances Offering of Affordable, Quality Medicare Advantage and Medicare Prescription Drug Plans in 2026
must have one or more of the following chronic conditions: cancer, cardiovascular disorders, chronic and disabling mental health conditions, chronic lung disorders, diabetes. There are other eligible conditions not listed. Eligibility for this benefit cannot be guaranteed based solely on your condition.
More news about: Peach State Health Plan